COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cellular Immunotherapy Study for Brain Cancer (alloCTL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01144247
Recruitment Status : Completed
First Posted : June 15, 2010
Last Update Posted : May 27, 2016
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:
The purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as aCTL cells, will be safe. This study will also try to determine if persons who receive aCTL's are more or less likely to survive their brain tumor than persons who had similar tumors in the past. Approximately 15 patients will be enrolled at UCLA.

Condition or disease Intervention/treatment Phase
Gliomas Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Mixed Glioma Glioblastoma Multiforme Malignant Meningioma Drug: alloreactive CTL Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas
Study Start Date : July 2010
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Arm Intervention/treatment
Experimental: alloreactive CTL arm Drug: alloreactive CTL
cellular immunotherapy with alloCTL

Primary Outcome Measures :
  1. Number of patients with adverse events as a measure of safety and tolerability [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Maximum tolerated dose [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


To participate in this clinical trial, patients must meet the following eligibility criteria:

  1. Subjects must have a histologically proven diagnosis of malignant glioma or meningioma and been treated with prior standard radiation and chemotherapy. There must be evidence of unequivocal progression by MRI.
  2. Tumor must be amenable to resection, and surgical resection must be clinically indicated.
  3. Age at least 18 years.
  4. Karnofsky performance scale score >60.
  5. Adequate hematologic function: a) systemic white blood cell count greater than 2 x 103/mm3, b) platelet count greater than 100,000/mm3, c) hematocrit greater than 25%.
  6. Adequate renal function, with creatinine less than two times the upper limit.
  7. Adequate hepatic function, with SGOT, alkaline phosphatase, and total bilirubin < 2x upper limit of normal.
  8. Patients must have an expected survival of at least three months.
  9. Patients must not have a history of HTLV, HIV, syphilis by RPR, hepatitis B and C.
  10. Patients must sign an informed consent.


Patients will be excluded from the trial if the patients:

  1. have multifocal tumors, bihemispheric tumors, infratentorial tumors, or non-surgically accessible tumors.
  2. have prior tumor resections where the ventricles were extensively breached.
  3. are pregnant or breast-feeding women.
  4. are females of child-bearing potential unable or unwilling to practice adequate birth control methods.
  5. have contraindications for brain MRI scanning (e.g., intra-ocular metal fragments, cerebral aneurysm clips, pacemaker).
  6. have concurrent malignancy, excluding curatively treated basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
  7. have concurrent systemic infection.
  8. have any clinically significant, uncontrolled medical illness, as determined by the investigators.
  9. are unwilling or unable to comply with procedures required in this protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01144247

Layout table for location information
United States, California
University of California, Los Angeles
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Publications of Results:
Kruse, C.A., Rubinstein, D. (2001) Cytotoxic T Lymphocytes Reactive to Patient Major Histocompatibility Proteins for Therapy of Recurrent Primary Brain Tumors, in Brain Tumor Immunotherapy, eds. L.M. Liau, D.P. Becker, T.F. Cloughsey, and D. Bigner, Humana Press, pp. 149-170

Other Publications:
Layout table for additonal information
Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT01144247    
Other Study ID Numbers: UCLA 07-09-008
R01CA125244 ( U.S. NIH Grant/Contract )
First Posted: June 15, 2010    Key Record Dates
Last Update Posted: May 27, 2016
Last Verified: May 2016
Keywords provided by Jonsson Comprehensive Cancer Center:
Recurrent Grade III or Grade IV Gliomas
anaplastic astrocytoma
anaplastic oligodendroglioma
anaplastic mixed glioma
glioblastoma multiforme
malignant meningioma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Vascular Tissue
Meningeal Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases